Outcomes of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Patients Aged 90 Years or Older

Mateen, Farrah J.; Nasser, Majeed; Spencer, Byron R.; Freeman, William D.; Shuaib, Ashfaq; Demaerschalk, Bart M.; Wijdicks, Eelco F. M.
April 2009
Mayo Clinic Proceedings;Apr2009, Vol. 84 Issue 4, p334
Academic Journal
Although age is a major risk factor for stroke, physicians are often reluctant to use thrombolytic agents in those who are very old. No published study provides detailed information on the use of intra. venous tissue plasminogen activator (tPA) in patients aged 90 years or older. We retrospectively reviewed the use of intravenous tPA for patients 90 years or older who were admitted with acute ischemic stroke to the hospital at 4 academic centers from March 1, 1999, to March 1, 2008. We reviewed the clinical features of the patients at presentation, complications, and outcomes. Twenty-two patients (11 women; median age, 93 years; range, 90-101 years) were identified who had received intravenous tPA for symptoms of acute ischemic stroke (average time to treatment, 143 minutes; range, 90-180 minutes; no tPA protocol violations; mean National Institutes of Health Stroke Scale score, 15; range, 5-28). Nearly all patients were highly functional at baseline (median modified Rankin Scale [mRS] score, 1; median Barthel index score, 95), and all but one performed the activities of daily living with little or no assistance before stroke. By the 30-day follow-up, 2 patients (9%) had a favorable outcome (mRS score, 0-2) and 2 (9%) had moderate disability (mRS score, 3). Most patients died (n=10) or experienced severe disability, defined as an mRS score of 4 or 5 (n=5). Asymptomatic intracerebral hemorrhage occurred in 3 patients (14%) and was nonfatal. Most patients aged 90 years or older who received intravenous tPA for acute ischemic stroke had poor 30-day functional outcomes or died. intravenous tPA treatment in this age group does not improve the outcome of ischemic stroke.


Related Articles

  • Alteplase: resistance to use among ER physicians.  // Reactions Weekly;5/21/2005, Issue 1052, p4 

    Focuses on the findings of a survey conducted by the American College of Emergency Physicians regarding the resistance of physicians to use alteplase (recombinant tissue plasminogen activator) in patients with acute ischaemic stroke. Main reason for resistance to use; Conclusion about reducing...

  • Early Ischemic Stroke Presentation in Pakistan. Kamal, Ayeesha Kamran; Khealani, Bhojo Asumal; Ansari, Sajjad Ahmed; Afridi, Maria; Syed, Nadir Ali // Canadian Journal of Neurological Sciences;Mar2009, Vol. 36 Issue 2, p181 

    Introduction: There are no studies from Pakistan that describe stroke presentation rates or factors associated with early or delayed presentation. This is important to know because current clinical protocols limit the use of recombinant tissue plasminogen activator (rtPA), the only available...

  • Imatinib increased therapeutic window for thrombolysis in ischemic stroke. Jacob, Harry S. // Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p29 

    The article discusses a study which suggests that imatinib can increase the time when patients suffering from a stroke can be treated with tissue plasminogen activator (TPA). The effect of TPA on a patient after three hours is stated. It also indicated the decrease in hemorrhage rate and the...

  • Reducing Door-to-Needle Time for tPA Use Remains an Elusive Goal in Stroke Care. Mitka, Mike // JAMA: Journal of the American Medical Association;4/6/2011, Vol. 305 Issue 13, p1288 

    The article discusses the challenge facing physicians in reducing door-to-needle time for administering tissue-type plasminogen activator (tPA) in patients with acute ischemic stroke. It references a study by Gregg C. Fonarow et al. published in the periodical "Circulation" in 2011. TPA is a...

  • Stroke outcomes in Thai elderly patients treated with and without intravenous thrombolysis. Dharmasaroja, Pornpatr A.; Muengtaweepongsa, Sombat; Pattaraarchachai, Junya; Permphan Dharmasaroja // Neurology International;2013, Vol. 5 Issue 3, p48 

    Higher mortality was found in very old patients with acute ischemic stroke treated with intravenous recombinant tissue-plasminogen activator (rtPA) as compared to younger patients. The benefit of thrombolytic treatment in this particular subgroup is still a subject of debate. The purpose of this...

  • Stroke subtypes, outcome and case fatality of ischemic stroke patients, treated with recombinant tissue plasminogen activator (r-tPA). Chandarsekherreddy, V.; Rinivasarao, B. V. C. S.; Prasad, V. V. S. R. K.; Prabha, T. S.; Jabeen, A. S.; Alladi, S.; Meena, Sitajayalaxmi A. K.; Rupam, B.; Kaul, S. // Annals of Indian Academy of Neurology;2007 Supplement 2, Vol. 10, p52 

    Background/Objective: There is not enough data about stroke thrombolysis from India. The present study was aimed to measure functional outcome, disability and death in thrombolysed patients of acute ischemic stroke, at the end of 12 months in a tertiary care center located in Hyderabad, Andhra...

  • Avoid rapid reduction of BP in this case.  // ED Nursing;Oct2009, Vol. 12 Issue 12, p136 

    The article offers information on limitations on the administration of the tissue-plasminogen activator (t-PA) to stroke patients in the U.S. It has been cited that patients with high blood pressure (BP) should not be given antihypertensives if it intends to normalize the BP of the patient. This...

  • Telestroke programs link stroke specialists to patients. Johnson, Cynthia // Medicine on the Net;Nov2009, Vol. 15 Issue 11, p1 

    The article focuses on the advantages of telestroke technology in improving the health of stroke patients. Stroke specialist Justin Sattin said that the burden of stroke decreases with the tissue plasminogen activator (tPA) since specialists can remotely treat patients in less time. Meanwhile,...

  • ED physicians more often sued for not giving tPA for stroke.  // ED Legal Letter;May2008, Vol. 19 Issue 5, p55 

    The article presents a study which found that emergency physicians are much more likely to be sued for not administering tissue plasminogen activator (tPA) to stroke patients than for giving the drug. Eighty-eight percent of the 33 lawsuits involving tPA and ischemic stroke claimed that injury...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics